目的 探讨银杏叶片治疗轻度认知功能损害患者的临床疗效和安全性.方法 将110例轻度认知功能损害患者随机分为两组,每组55例,研究组口服银杏叶片治疗,对照组口服丹参片治疗,观察3个月.于治疗前后采用简易智力状态检查量表和日常生活能力量表评定临床疗效,及时记录各种不良反应.结果 治疗后研究组简易智力状态检查量表评分较治疗前显著升高（P＜0.01）,日常生活能力量表评分较治疗前显著下降（P＜0.05）;对照组简易智力状态检查量表评分较治疗前有升高趋势,日常生活能力量表评分较治疗前有下降趋势,但差异均无显著性（P＞0.05）.治疗后研究组简易智力状态检查量表评分显著高于对照组（P＜0.01）.两组均未见明显不良反应.结论 银杏叶片与丹参片治疗轻度认知功能损害患者均有效,且安全性高,依从性好,但银杏叶片疗效显著优于丹参片.
Objective To explore the efficacy and safety of ginkgo leaf tablet in the treatment of mild cognitive impairment（MCI）. Methods One hundred and ten MCI patients were randomly assigned to two groups of 55 ones each, research group took orally ginkgo leaf tablet and control group did salvia tablet for 3 months. Efficacies were assessed with the Mini-mental State Examination （MMSE） and Activity of Daily Living Scale （ADL） before and after treatment and adverse reactions recorded in time. Results After treatment the MMSE score heightened more significantly （P〈0.01） and the ADL lowered （P〈0.05） in research group compared with pretreatment; after treatment the MMSE score showed increasing trend and the ADL decreasing trend in control group compared with pretreatment, but differences were not significant （P〈0. 05）. After treatment the MMSE score was significantly higher in research than in control group （P〈0.01）. Both groups had no obvious adverse reactions. Conclusion Both ginkgo leaf and salvia tablet are effective in the treatment of mild cognitive impairment, have higher safety and better compliance, but ginkgo leaf tablet has an advantage over salvia tablet in efficacy.
Journal of Clinical Psychosomatic Diseases